Building upon the division’s strong legacy in the field of Inflammatory Bowel Disease (IBD), Dr. Longman will oversee and expand clinical, research and educational activities at the JRC.
The innate immune system is the body’s first line of defense against invading pathogens, but there has been a lack of information on what a “healthy” innate immune system looks like.
Dr. Guo’s lab will use a combination of bioinformatics, bacterial genetics, metabolomics, and mouse models to identify the molecular mechanisms behind host-microbiome interaction.
In his new role, Dr. Brown will continue to provide expertise as a Clinical Director while developing programs in faculty development across all of the department’s missions.
The project, set to begin in January 2018, is focused on determining whether the chemopreventive effects of the COX-2 inhibitor celecoxib are exerted, in part, through altering the intestinal microbiota and gut luminal metabolites.
Dr. David Cohen's laboratory is leading the frontiers of molecular regulation of nutrient metabolism and energy homeostasis by membrane lipids, with an emphasis on state-of-the-art research and novel collaborations.
A breakthrough paper has been published in Nature revealing that the immune system and the neuronal system work together inside the gut to respond to infection.
This non-invasive procedure, called endoscopic sleeve gastroplasty (ESG), is bringing new hope for people who want to lose 40 pounds or more and has been added to a list of options targeted to the reduction of obesity.
Dr. Iliyan Iliev has won the Kenneth Rainin Foundation's Breakthrough Award (2016) for his study on the role of mycobiota during immunomodulatory therapy for inflammatory bowel disease.
Dr. Julie Magarian Blander is the recipient of significant funding from the National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Burroughs Wellcome Trust Fund, and Leukemia and Lymphoma Society Scholar Award.
